Publications

  1. Hedin KE, Bell MP, Kalli KR, Huntoon CJ, Sharp BM, McKean DJ. Delta-opioid receptors expressed by Jurkat T cells enhance IL-2 secretion by increasing AP-1 complexes and activity of the NF-AT/AP-1-binding promoter element. J Immunol. 1997 Dec 1; 159(11):5431-40.
    View PubMed
  2. Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GG, Kalli KR, Jenkins RB. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res. 1998 Feb 1; 238(2):439-49.
    View PubMed
  3. Kalli K, Huntoon C, Bell M, McKean DJ. Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB. Mol Cell Biol. 1998 Jun; 18(6):3140-8.
    View PubMed
  4. Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, Kalli KR, Conover CA. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 1999 Oct 15; 59(20):5370-5.
    View PubMed
  5. Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, Huang H, Hartmann LC, Kaufmann SH, Smith DI. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001 May 15; 61(10):4258-65.
    View PubMed
  6. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001 Aug 1; 61(15):5895-904.
    View PubMed
  7. Bankers-Fulbright JL, Kalli KR, McKean DJ. Interleukin-1 signal transduction. Life Sci. 1996; 59(2):61-83.
    View PubMed
  8. Walsh RJ, Reinot T, Hayes JM, Kalli KR, Hartmann LC, Small GJ. Nonphotochemical hole burning spectroscopy of a mitochondrial selective rhodamine dye molecule in normal and cancerous ovarian surface epithelial cells. Journal of Luminescence. 2002 Jul; 98(1-4):115-21.
    View PubMed
  9. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology. 2002 Sep; 143(9):3259-67.
    View PubMed
  10. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002 Aug 15; 62(16):4656-62.
    View PubMed
  11. Denison SR, Becker NA, Ferber MJ, Phillips LA, Kalli KR, Lee J, Lillie J, Smith DI, Shridhar V. Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer. Genes Chromosomes Cancer. 2002 Aug; 34(4):406-15.
    View PubMed
  12. Walsh RJ, Matsuzaki S, Reinot T, Hayes JM, Kalli KR, Hartmann LC, Small GJ. Single-cell nonphotochemical hole burning of ovarian surface epithelial carcinoma and normal cells. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1685-9. Epub 2003 Feb 06.
    View PubMed
  13. Kalli KR, Conover CA. The insulin-like growth factor/insulin system in epithelial ovarian cancer. Front Biosci. 2003 May 01; 8:d714-22.
    View PubMed
  14. Walsh RJ, Reinot T, Hayes JM, Kalli KR, Hartmann LC, Small GJ. Carcinoma and SV40-transfected normal ovarian surface epithelial cell comparison by nonphotochemical hole burning. Biophys J. 2003 Feb; 84(2 Pt 1):1299-307.
    View PubMed
  15. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res. 2003 Sep 1; 9(10 Pt 1):3534-45.
    View PubMed
  16. Session DR, Kalli KR, Tummon IS, Damario MA, Dumesic DA. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol. 2003 Oct; 17(5):405-7.
    View PubMed
  17. Kalli KR, Devine KE, Cabot MC, Arnt CR, Heldebrant MP, Svingen PA, Erlichman C, Hartmann LC, Conover CA, Kaufmann SH. Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. Mol Pharmacol. 2003 Dec; 64(6):1434-43.
    View PubMed
  18. Kalli KR , Chen BK , Bale LK , Gernand E , Overgaard MT , Oxvig C , Cliby WA , Conover CA . Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells. Int J Cancer 2004 Jul 10; 110 (5):633-40
    View PubMed
  19. Kalli KR, Bradley SV, Fuchshuber S, Conover CA. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer. Gynecol Oncol. 2004 Sep; 94(3):705-12.
    View PubMed
  20. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005 Mar 15; 11(6):2149-55.
    View PubMed
  21. Tebben PJ, Kalli KR, Cliby WA, Hartmann LC, Grande JP, Singh RJ, Kumar R. Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc. 2005 Jun; 80(6):745-51.
    View PubMed
  22. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res. 2006 Jan 1; 66(1):362-71.
    View PubMed
  23. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest. 2006 Jul; 116(7):1994-2004. Epub 2006 Jun 08.
    View PubMed
  24. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol. 2006 Sep 10; 24(26):4254-61. Epub 2006 Aug 14.
    View PubMed
  25. Williams TI, Toups KL, Saggese DA, Kalli KR, Cliby WA, Muddiman DC. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res. 2007 Aug; 6(8):2936-62. Epub 2007 Jun 21.
    View PubMed
  26. Kalli KR. MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer. Curr Opin Investig Drugs. 2007 Dec; 8(12):1067-73.
    View PubMed
  27. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008 Mar; 108(3):619-26. Epub 2008 Jan 28.
    View PubMed
  28. Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML, Knutson KL. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood. 2008 Feb 1; 111(3):1472-9. Epub 2007 Nov 20.
    View PubMed
  29. Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res. 2008 Jun 15; 68(12):4893-901.
    View PubMed
  30. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009 Apr 1; 69(7):2887-95. Epub 2009 Mar 10.
    View PubMed
  31. Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunol Immunother. 2010 Jan; 59(1):161-71. Epub 2009 Jul 21.
    View PubMed
  32. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS, Knutson KL. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One. 2009; 4(7):e6292. Epub 2009 Jul 20.
    View PubMed
  33. He W, Kularatne SA, Kalli KR, Prendergast FG, Amato RJ, Klee GG, Hartmann LC, Low PS. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer. 2008 Oct 15; 123(8):1968-73.
    View PubMed
  34. Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM. Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem. 2008 Nov; 318(1-2):89-99. Epub 2008 Jul 12.
    View PubMed
  35. Ogata Y, Heppelmann CJ, Charlesworth MC, Madden BJ, Miller MN, Kalli KR, Cilby WA, Bergen HR 3rd, Saggese DA, Muddiman DC. Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. J Proteome Res. 2006 Dec; 5(12):3318-25.
    View PubMed
  36. Peedicayil A, Vierkant RA, Hartmann LC, Fridley BL, Fredericksen ZS, White KL, Elliott EA, Phelan CM, Tsai YY, Berchuck A, Iversen ES Jr, Couch FJ, Peethamabaran P, Larson MC, Kalli KR, Kosel ML, Shridhar V, Rider DN, Liebow M, Cunningham JM, Schildkraut JM, Sellers TA, Goode EL. JM, Sellers TA, Goode EL. Risk of ovarian cancer and inherited variants in relapse-associated genes. PLoS One. 2010; 5(1):e8884. Epub 2010 Jan 27.
    View PubMed
  37. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM, Cunningham JM, Hartmann LC. Inherited determinants of ovarian cancer survival. Clin Cancer Res. 2010 Feb 1; 16(3):995-1007. Epub 2010 Jan 26.
    View PubMed
  38. Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res. 2010 Feb 1; 16(3):825-34. Epub 2010 Jan 26.
    View PubMed
  39. White KL, Sellers TA, Fridley BL, Vierkant RA, Phelan CM, Tsai YY, Kalli KR, Berchuck A, Iversen ES, Hartmann LC, Liebow M, Armasu S, Fredericksen Z, Larson MC, Duggan D, Couch FJ, Schildkraut JM, Cunningham JM, Goode EL. Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer. Twin Res Hum Genet. 2010 Feb; 13(1):43-56.
    View PubMed
  40. White KL, Rider DN, Kalli KR, Knutson KL, Jarvik GP, Goode EL. Genomics of the NF-kappaB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes Control. 2011 May; 22(5):785-801. Epub 2011 Feb 27.
    View PubMed
  41. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011 Mar 15; 17(6):1591-602. Epub 2011 Jan 28.
    View PubMed
  42. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011 Apr; 3(4):539-56.
    View PubMed
  43. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011 Jun 15; 186(12):6905-13. Epub 2011 May 06.
    View PubMed
  44. Peethambaram P, Fridley BL, Vierkant RA, Larson MC, Kalli KR, Elliott EA, Oberg AL, White KL, Rider DN, Keeney GL, Cunningham JM, Hartmann LC, Goode EL. Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. Int J Mol Epidemiol Genet. 2011; 2(2):185-95. Epub 2011 May 02.
    View PubMed
  45. Goetzl EJ, Lee H, Dolezalova H, Kalli KR, Conover CA, Hu YL, Azuma T, Stossel TP, Karliner JS, Jaffe RB. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann N Y Acad Sci. 2000 Apr; 905:177-87.
    View PubMed
  46. Kalli KR, Fearon DT. Binding of C3b and C4b by the CR1-like site in murine CR1. J Immunol. 1994 Mar 15; 152(6):2899-903.
    View PubMed
  47. Kalli KR, Hsu P, Fearon DT. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol. 1994; 15(4):417-31.
    View PubMed
  48. Kalli KR, Hsu PH, Bartow TJ, Ahearn JM, Matsumoto AK, Klickstein LB, Fearon DT. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor. J Exp Med. 1991 Dec 1; 174(6):1451-60.
    View PubMed
  49. Martin DR, Yuryev A, Kalli KR, Fearon DT, Ahearn JM. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J Exp Med. 1991 Dec 1; 174(6):1299-311.
    View PubMed
  50. Kalli KR, Ahearn JM, Fearon DT. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. J Immunol. 1991 Jul 15; 147(2):590-4.
    View PubMed
  51. Conrad DH, Keegan AD, Kalli KR, Van Dusen R, Rao M, Levine AD. Superinduction of low affinity IgE receptors on murine B lymphocytes by lipopolysaccharide and IL-4. J Immunol. 1988 Aug 15; 141(4):1091-7.
    View PubMed
  52. Miles SL, Niles RM, Pittock S, Vile R, Davies J, Winters JL, Abu-Yaghi NE, Grothey A, Siddiqui M, Kaur J, Hartmann L, Kalli KR, Pease L, Kravitz D, Markovic S, Pulido JS. A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes. Retina. 2012 Oct; 32(9):1959-66.
    View PubMed
  53. Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB, Knutson KL. MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB, Knutson KL. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One. 2013; 8(1):e53903. Epub 2013 Jan 30.
    View PubMed
  54. Torres ML, Hartmann LC, Cliby WA, Kalli KR, Young PM, Weaver AL, Langstraat CL, Jatoi A, Kumar S, Mariani A. Nutritional status, CT body composition measures and survival in ovarian cancer. Gynecol Oncol. 2013 Jun; 129(3):548-53. Epub 2013 Mar 21.
    View PubMed
  55. Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, Winham SJ, Vierkant RA, Rider DN, Block MS, Klotzle B, Konecny G, Winterhoff BJ, Hamidi H, Shridhar V, Fan JB, Visscher DW, Olson JE, Hartmann LC, Bibikova M, Chien J, Cunningham JM, Goode EL. JM, Goode EL. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum Mol Genet. 2013 Aug 1; 22(15):3038-47. Epub 2013 Apr 09.
    View PubMed
  56. Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 2013; 33(2):137-64.
    View PubMed
  57. White KL, Vierkant RA, Fogarty ZC, Charbonneau B, Block MS, Pharoah PD, Chenevix-Trench G, for AOCS/ACS group;, Rossing MA, Cramer DW, Pearce CL, Schildkraut JM, Menon U, Kjaer SK, Levine DA, Gronwald J, Culver HA, Whittemore AS, Karlan BY, Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean Y, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, Schwaab I, Hogdall CK, Lundvall L, Olson SH, Orlow I, Paddock LE, Rudolph A, Eilber U, Dansonka-Mieszkowska A, Rzepecka IK, Ziolkowska-Seta I, Brinton L, Yang H, Garcia-Closas M, Despierre E, Lambrechts S, Vergote I, Walsh C, Lester J, Sieh W, McGuire V, Rothstein JH, Ziogas A, Lubinski J, Cybulski C, Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, Van Denberg D, Terry KL, Vitonis AF, Doherty JA, Johnatty SE, Defazio A, Song H, Tyrer J, Sellers TA, Phelan CM, Kalli KR, Cunningham JM, Fridley BL, Goode EL. Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean Y, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, et al. Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):987-92. Epub 2013 Mar 19.
    View PubMed
  58. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Australian Cancer Study, Australian Ovarian Cancer Study Group, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dork T, du Bois A, Durst M, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q, Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Hogdall E, Hogdall CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubinski J, Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM, Permuth-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shen H, Shridhar V, Shu XO, Sieh W, Southey MC, Spellman P, Tajima K, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, van Altena AM, van den Berg D, Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wik E, Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng W, Ziogas A, Zulkifli F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA. Cancer Study Group, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013 Apr; 45(4):362-70, 370e1-2.
    View PubMed
  59. Pulido JS, Flotte TJ, Raja H, Miles S, Winters JL, Niles R, Jaben EA, Markovic SN, Davies J, Kalli KR, Vile RG, Garcia JJ, Salomao DR. Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation. Eye (Lond). 2013 Sep; 27(9):1058-62. Epub 2013 Jun 21.
    View PubMed
  60. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Australian Cancer Study, Australian Ovarian Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Consortium of Investigators of Modifiers of BRCA1/2, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dork T, du Bois A, Durst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Gorski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Hogdall CK, Hogdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubinski J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun. 2013; 4:1627.
    View PubMed
  61. Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, Knutson KL, Block MS. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1730-5. Epub 2013 Jul 22.
    View PubMed
  62. Derycke MS, Charbonneau B, Preston CC, Kalli KR, Knutson KL, Rider DN, Goode EL. Toward understanding the genetics of regulatory T cells in ovarian cancer. Oncoimmunology. 2013 Jun 1; 2(6):e24535. Epub 2013 Apr 16.
    View PubMed
  63. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Hogdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjaer SK, Jensen A, Hogdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, Garcia-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. RK, Kjaer SK, Jensen A, Hogdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, Garcia-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013 Aug; 14(9):853-62. Epub 2013 Jul 09.
    View PubMed
  64. Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Mol Cancer Ther. 2013 Dec; 12(12):2909-16. Epub 2013 Oct 15.
    View PubMed
  65. Kobel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL, Ovarian Tumor Tissue Analysis consortium. Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL, Ovarian Tumor Tissue Analysis consortium. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1677-86. Epub 2013 Jul 23.
    View PubMed
  66. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One. 2013; 8(11):e80063. Epub 2013 Nov 14.
    View PubMed
  67. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Kobel M, PRACTICAL Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubinski J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Hogdall CK, Hogdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Durst M, du Bois A, Dork T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA, Australian Ovarian Cancer Study Group, Australian Cancer Study, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Pearce CL. Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013; 4:1628.
    View PubMed
  68. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, Shridhar V, Bell DA, April C, Bentley D, Bibikova M, Cheetham RK, Fan JB, Grocock R, Humphray S, Kingsbury Z, Peden J, Chien J, Swisher EM, Hartmann LC, Kalli KR, Goode EL, Sicotte H, Kaufmann SH, Harris RS. Kingsbury Z, Peden J, Chien J, Swisher EM, Hartmann LC, Kalli KR, Goode EL, Sicotte H, Kaufmann SH, Harris RS. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013 Dec 15; 73(24):7222-31. Epub 2013 Oct 23.
    View PubMed
  69. Australian Cancer Study//Australian Ovarian Cancer Study//Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)//Gene Environment Interaction and Breast Cancer (GENICA)//Swedish Breast Cancer Study (SWE-BRCA)//Hereditary Breast and Ovarian Cancer Research Grou, et al , Bojesen SE , Pooley KA , Johnatty SE , Beesley J , Michailidou K , Tyrer JP , Edwards SL , Pickett HA , Shen HC , Smart CE , Hillman KM , Mai PL , Lawrenson K , Stutz MD , Lu Y , Karevan R , Woods N , Johnston RL , French JD , Chen X , Weischer M , Nielsen SF , Maranian MJ , Ghoussaini M , Ahmed S , Baynes C , Bolla MK , Wang Q , Dennis J , McGuffog L , Barrowdale D , Lee A , Healey S , Lush M , Tessier DC , Vincent D , Bacot F , Vergote I , Lambrechts S , Despierre E , Risch HA , Gonzalez-Neira A , Rossing MA , Pita G , Doherty JA , Alvarez N , Larson MC , Fridley BL , Schoof N , Chang-Claude J , Cicek MS , Peto J , Kalli KR , Broeks A , Armasu SM , Schmidt MK , Braaf LM , Winterhoff B , Nevanlinna H , Konecny GE , Lambrechts D , Rogmann L , Guenel P , Teoman A , Milne RL , Garcia JJ , Cox A , Shridhar V , Burwinkel B , Marme F , Hein R , Sawyer EJ , Haiman CA , Wang-Gohrke S , Andrulis IL , Moysich KB , Hopper JL , Odunsi K , Lindblom A , Giles GG , Brenner H , Simard J , Lurie G , Fasching PA , Carney ME , Radice P , Wilkens LR , Swerdlow A , Goodman MT , Brauch H , Garcia-Closas M , Hillemanns P , Winqvist R , Durst M , Devilee P , Runnebaum I , Jakubowska A , Lubinski J , Mannermaa A , Butzow R , Bogdanova NV , Dork T , Pelttari LM , Zheng W , Leminen A , Anton-Culver H , Bunker CH , Kristensen V , Ness RB , Muir K , Edwards R , Meindl A , Heitz F , Matsuo K , du Bois A , Wu AH , Harter P , Teo SH , Schwaab I , Shu XO , Blot W , Hosono S , Kang D , Nakanishi T , Hartman M , Yatabe Y , Hamann U , Karlan BY , Sangrajrang S , Kjaer SK , Gaborieau V , Jensen A , Eccles D , Hogdall E , Shen CY , Brown J , Woo YL , Shah M , Azmi MA , Luben R , Omar SZ , Czene K , Vierkant RA , Nordestgaard BG , Flyger H , Vachon C , Olson JE , Wang X , Levine DA , Rudolph A , Weber RP , Flesch-Janys D , Iversen E , Nickels S , Schildkraut JM , Silva , Cramer DW , Gibson L , Terry KL , Fletcher O , Vitonis AF , van der Schoot CE , Poole EM , Hogervorst FB , Tworoger SS , Liu J , Bandera EV , Li J , Olson SH , Humphreys K , Orlow I , Blomqvist C , Rodriguez-Rodriguez L , Aittomaki K , Salvesen HB , Muranen TA , Wik E , Brouwers B , Krakstad C , Wauters E , Halle MK , Wildiers H , Kiemeney LA , Mulot C , Aben KK , Laurent-Puig P , Altena AM , Truong T , Massuger LF , Benitez J , Pejovic T , Perez JI , Hoatlin M , Zamora MP , Cook LS , Balasubramanian SP , Kelemen LE , Schneeweiss A , Le ND , Sohn C , Brooks-Wilson A , Tomlinson I , Kerin MJ , Miller N , Cybulski C , Henderson BE , Menkiszak J , Schumacher F , Wentzensen N , Le Marchand L , Yang HP , Mulligan AM , Glendon G , Engelholm SA , Knight JA , Hogdall CK , Apicella C , Gore M , Tsimiklis H , Song H , Southey MC , Jager A , den Ouweland AM , Brown R , Martens JW , Flanagan JM , Kriege M , Paul J , Margolin S , Siddiqui N , Severi G , Whittemore AS , Baglietto L , McGuire V , Stegmaier C , Sieh W , Muller H , Arndt V , Labreche F , Gao YT , Goldberg MS , Yang G , Dumont M , Sellers TA , Jones M , Figueroa J , Szabo CI , Kennedy MJ , Cole T , Slager S , Pankratz VS .oussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F, Australian Cancer Study, Australian Ovarian Cancer Study, Kathleen Cuningham Foundation Consortium for Research i Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013 Apr; 45 (4):371-84, 384e1-2
    View PubMed
  70. Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, Keeney GL, Oberg TN, Cunningham JM, Beesley J, Johnatty SE, Chen X, Goodman KE, Armasu SM, Rider DN, Sicotte H, Schmidt MM, Elliott EA, Hogdall E, Kjaer SK, Fasching PA, Ekici AB, Lambrechts D, Despierre E, Hogdall C, Lundvall L, Karlan BY, Gross J, Brown R, Chien J, Duggan DJ, Tsai YY, Phelan CM, Kelemen LE, Peethambaram PP, Schildkraut JM, Shridhar V, Sutphen R, Couch FJ, Sellers TA, Ovarian Cancer Association Consortium. Fasching PA, Ekici AB, Lambrechts D, Despierre E, Hogdall C, Lundvall L, Karlan BY, Gross J, Brown R, Chien J, Duggan DJ, Tsai YY, Phelan CM, Kelemen LE, Peethambaram PP, Schildkraut JM, Shridhar V, Sutphen R, Couch FJ, Sellers TA, et al. Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1638-48. Epub 2011 Jul 01.
    View PubMed
  71. Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014 Mar 1; 20(5):1288-97. Epub 2014 Jan 07.
    View PubMed
  72. for AOCS/ACS group, Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeney LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dork T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dork T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Risk of ovarian cancer and the NF-kappaB pathway: genetic association with IL1A and TNFSF10. Cancer Res 2014 Feb 1; 74 (3):852-61 Epub 2013 Nov 22
    View PubMed
  73. Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PP, Goode EL. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep. 2014; 4:4026. Epub 2014 Feb 07.
    View PubMed
  74. Koestler DC, Chalise P, Cicek MS, Cunningham JM, Armasu S, Larson MC, Chien J, Block M, Kalli KR, Sellers TA, Fridley BL, Goode EL. Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. BMC Med Genomics. 2014; 7:8. Epub 2014 Jan 30.
    View PubMed
  75. Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC, Konecny GE, Winterhoff B, Fan JB, Bibikova M, Chien J, Shridhar V, Block MS, Hartmann LC, Visscher DW, Cunningham JM, Knutson KL, Fridley BL, Goode EL. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. Cancer Res. 2014 Jun 1; 74(11):3084-91. Epub 2014 Apr 11.
    View PubMed
  76. Winham SJ, Armasu SM, Cicek MS, Larson MC, Cunningham JM, Kalli KR, Fridley BL, Goode EL. Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Genet Epidemiol. 2014 Jul; 38(5):457-66. Epub 2014 May 22.
    View PubMed
  77. Karyampudi L , Lamichhane P , Scheid AD , Kalli KR , Shreeder B , Krempski JW , Behrens MD , Knutson KL . Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 2014 Jun 1; 74 (11):2974-85 Epub 2014 Apr 11
    View PubMed
  78. Fridley BL, Armasu SM, Cicek MS, Larson MC, Wang C, Winham SJ, Kalli KR, Koestler DC, Rider DN, Shridhar V, Olson JE, Cunningham JM, Goode EL. Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome. BMC Med Genomics. 2014; 7:21. Epub 2014 Apr 28.
    View PubMed
  79. Georgia Chenevix-Trench//for AOCS///ACS Group, Block MS , Charbonneau B , Vierkant RA , Fogarty Z , Bamlet WR , Pharoah PD , Rossing MA , Cramer D , Pearce CL , Schildkraut J , Menon U , Kjaer SK , Levine DA , Gronwald J , Culver HA , Whittemore AS , Karlan BY , Lambrechts D , Wentzensen N , Kupryjanczyk J , Chang-Claude J , Bandera EV , Hogdall E , Heitz F , Kaye SB , Fasching PA , Campbell I , Goodman MT , Pejovic T , Bean YT , Hays LE , Lurie G , Eccles D , Hein A , Beckmann MW , Ekici AB , Paul J , Brown R , Flanagan JM , Harter P , du Bois A , Schwaab I , Hogdall CK , Lundvall L , Olson SH , Orlow I , Paddock LE , Rudolph A , Eilber U , Dansonka-Mieszkowska A , Rzepecka IK , Ziolkowska-Seta I , Brinton LA , Yang H , Garcia-Closas M , Despierre E , Lambrechts S , Vergote I , Walsh CS , Lester J , Sieh W , McGuire V , Rothstein JH , Ziogas A , Lubinski J , Cybulski C , Menkiszak J , Jensen A , Gayther SA , Ramus SJ , Gentry-Maharaj A , Berchuck A , Wu AH , Pike MC , Van Den Berg D , Terry KL , Vitonis AF , Ramirez SM , Rider DN , Knutson KL , Sellers TA , Phelan CM , Doherty JA , Johnatty SE , deFazio A , Song H , Tyrer J , Kalli KR , Fridley BL , Cunningham JM , Goode EL . Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean YT, Hays LE, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, et al. Variation in NF-kappaB signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2014 Jul; 23 (7):1421-7 Epub 2014 Apr 16
    View PubMed
  80. Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, Heman-Ackah SM, von Hofe E, Wettstein PJ, Mohamadzadeh M, Knutson KL. MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. J Immunol. 2011 Jul 1; 187(1):316-24. Epub 2011 May 25.
    View PubMed
  81. Konecny GE , Wang C , Hamidi H , Winterhoff B , Kalli KR , Dering J , Ginther C , Chen HW , Dowdy S , Cliby W , Gostout B , Podratz KC , Keeney G , Wang HJ , Hartmann LC , Slamon DJ , Goode EL . Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 2014 Oct; 106 (10) Epub 2014 Sept 30
    View PubMed
  82. Kobel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Hogdall E, Jensen A, Hogdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L, AOCS Study Group, Goode EL, Kjaer SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE. BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. 2014 Dec 9; 111(12):2297-307. Epub 2014 Oct 30.
    View PubMed
  83. Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015 Jan 1; 75(1):22-30. Epub 2014 Nov 14.
    View PubMed
  84. Wahner Hendrickson AE , Hawthorne KM , Goode EL , Kalli KR , Goergen KM , Bakkum-Gamez JN , Cliby WA , Keeney GL , Visscher DW , Tarabishy Y , Oberg AL , Hartmann LC , Maurer MJ . Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecol Oncol 2015 Apr; 137 (1):77-85 Epub 2015 Jan 22
    View PubMed
  85. Bogani G, Liu MC, Dowdy SC, Cliby WA, Kerr SE, Kalli KR, Kipp BR, Halling KC, Campion MB, Mariani A. Detection of circulating tumor cells in high-risk endometrial cancer. Anticancer Res. 2015 Feb; 35(2):683-7.
    View PubMed
  86. Block MS , Maurer MJ , Goergen K , Kalli KR , Erskine CL , Behrens MD , Oberg AL , Knutson KL . Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine 2015 May; 73 (1):108-13 Epub 2015 Mar 03
    View PubMed
  87. Lodhia K, Becker M, Hou X, Kalli K, Harrell M, Wilcoxen K, Swisher E, Weroha S, Halsuka P. P7.01Characterization of 148 Ovarian Cancer tumografts (Avatars) using BROCA-HR deep sequencing. Ann Oncol. 2015 Mar; 26 Suppl 2:ii31.
    View PubMed
  88. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, deFazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubilski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlow I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, Menon U, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G, AOCS group, Acs, Pharoah PD, Gayther SA, Ness RB, Odunsi K, Sucheston LE, Knutson KL, Goode EL. Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubilski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, et Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res. 2014 Apr; 2(4):332-40. Epub 2014 Jan 27.
    View PubMed
  89. Chien J , Sicotte H , Fan JB , Humphray S , Cunningham JM , Kalli KR , Oberg AL , Hart SN , Li Y , Davila JI , Baheti S , Wang C , Dietmann S , Atkinson EJ , Asmann YW , Bell DA , Ota T , Tarabishy Y , Kuang R , Bibikova M , Cheetham RK , Grocock RJ , Swisher EM , Peden J , Bentley D , Kocher JP , Kaufmann SH , Hartmann LC , Shridhar V , Goode EL . Bentley D, Kocher JP, Kaufmann SH, Hartmann LC, Shridhar V, Goode EL. TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Res 2015 Aug 18; 43 (14):6945-58 Epub 2015 Apr 27
    View PubMed
  90. Mehner C , Oberg AL , Kalli KR , Nassar A , Hockla A , Pendlebury D , Cichon MA , Goergen KM , Maurer MJ , Goode EL , Keeney GL , Jatoi A , Sahin-Toth M , Copland JA , Radisky DC , Radisky ES . Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget 2015 Nov 3; 6 (34):35737-54
    View PubMed
  91. Jatoi A, Foster NR, Kalli KR, Vierkant RA, Zhang Z, Larson MC, Fridley B, Goode EL. Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival. BMC Cancer. 2015; 15:711. Epub 2015 Oct 15.
    View PubMed
  92. Knutson KL , Maurer MJ , Preston CC , Moysich KB , Goergen K , Hawthorne KM , Cunningham JM , Odunsi K , Hartmann LC , Kalli KR , Oberg AL , Goode EL . Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother 2015 Dec; 64 (12):1495-504 Epub 2015 Aug 23
    View PubMed
  93. Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE, Dietz AB, Goode EL, Knutson KL. PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-kappaB. Cancer Res 2016 Jan 15; 76 (2):239-50 Epub 2015 Nov 13
    View PubMed
  94. Swisher EM , Harrell MI , Norquist BM , Walsh T , Brady M , Lee M , Hershberg R , Kalli KR , Lankes H , Konnick EQ , Pritchard CC , Monk BJ , Chan JK , Burger R , Kaufmann SH , Birrer MJ . Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol 2016 Mar 1; 2 (3):370-2
    View PubMed
  95. Winterhoff B , Hamidi H , Wang C , Kalli KR , Fridley BL , Dering J , Chen HW , Cliby WA , Wang HJ , Dowdy S , Gostout BS , Keeney GL , Goode EL , Konecny GE . Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecol Oncol 2016 Apr; 141 (1):95-100
    View PubMed
  96. Leonard B , Starrett GJ , Maurer MJ , Oberg A , Van Bockstal M , Van Dorpe J , De Wever O , Helleman J , Sieuwerts AM , Berns EM , Martens JW , Anderson B , Brown WL , Kalli KR , Kaufmann SH , Harris RS . APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma. Clin Cancer Res 2016 Mar 25 [Epub ahead of print]
    View PubMed